deltatrials
Completed PHASE3 NCT00012389

Irinotecan With or Without Oxaliplatin in Treating Patients With Metastatic Colorectal Cancer

A Multicenter, Open-Label, Randomized, Two-Arm Study of Irinotecan (CPT-11) Versus the Combination of Oxaliplatin + Irinotecan (CPT-11) as Second-Line Treatment of Metastatic Colorectal Carcinoma

Sponsor: Sanofi

Conditions Colorectal Cancer
Interventions irinotecan hydrochloride oxaliplatin
Updated 6 times since 2017 Last updated: Dec 18, 2013 Started: Dec 31, 2000 Completion: Oct 31, 2008

Listed as NCT00012389, this PHASE3 trial focuses on Colorectal Cancer and remains completed. Sponsored by Sanofi, it has been updated 6 times since 2000, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Change History

6 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

▶ Show 1 earlier version

  1. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE3

    First recorded

Dec 2000

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Sanofi
Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aberdeen, United Kingdom, Albany, United States, Aracaiu-SE, Brazil, Arlington Heights, United States, Aurora, United States, Austin, United States, Baltimore, United States, Barrie, Canada, Baton Rouge, United States, Belo Horizonte-MG, Brazil and 118 more location s